Lixumistat (acetate)

Lixumistat (IM156; HL156A; HL271) acetate, a chemical derivative of Metformin (HY-B0627), is a potent and orally active AMPK activator that increases AMPK phosphorylation. Lixumistat (acetate) attenuates aging-associated cognitive impairment in animal model[1][2]. Lixumistat (acetate) is a potent oxidative phosphorylation (OXPHOS) inhibitor which can be used for the research of solid tumors[3].

Product Specifications

CAS Number

[1422365-94-3]

Product Name Alternative

IM156; HL156A; HL271 (acetate)

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

AMPK; Oxidative Phosphorylation

Type

Reference compound

Related Pathways

Epigenetics; Metabolic Enzyme/Protease; PI3K/Akt/mTOR

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/lixumistat-acetate.html

Purity

99.88

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

N=C(N1CCCC1)NC(NC2=CC=C(OC(F)(F)F)C=C2)=N.CC(O)=O

Molecular Formula

C15H20F3N5O3

Molecular Weight

375.35

Precautions

H315, H319, H335

References & Citations

[1]Row H, et al. HL271, a novel chemical compound derived from metformin, differs from metformin in its effects on the circadian clock and metabolism. Biochem Biophys Res Commun. 2016 Jan 15;469 (3) :783-9.|[2]Bang E, et al. The Improving Effect of HL271, a Chemical Derivative of Metformin, a Popular Drug for Type II Diabetes Mellitus, on Aging-induced Cognitive Decline. Exp Neurobiol. 2018 Feb;27 (1) :45-56.|[3]Sun Young Rha, et al. Phase I study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology 38 (15_suppl) :3590-3590.